Product Information

Registration Status: Active

TUKYSA (TUCATINIB) FILM-COATED TABLETS 150 mg is approved to be sold in Singapore with effective from 2020-05-19. It is marketed by NYPRAX PHARMA PTE LTD, with the registration number of SIN15942P.

This product contains Tucatinib 150mg in the form of TABLET, FILM COATED. It is approved for ORAL use.

This product is manufactured by Corden Pharma GmbH (Finished Tablets) in GERMANY,Tjoapack Netherlands B.V in NETHERLANDS, andHovione FarmaCiencia S.A (SDD intermediate) in PORTUGAL.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.



Tucatinib has been used in trials studying the treatment of HER2 Positive Breast Cancers and HER2 Positive Metastatic Breast Cancers.

Mechanism of Action

Tucatinib is a selective, orally-active inhibitor of ErbB-2, a receptor kinase target that has been found to be over-expressed in breast, ovarian and stomach cancers and other cancers. The growth factor receptor tyrosine kinase ErbB-2 plays a major role in controlling cell growth and differentiation.

Active Ingredient/Synonyms

Tucatinib | Tucatinib |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank